SNWV

Business Context and Reporting Period

Company: SANUWAVE Health, Inc. (SNWV)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Sanuwave commercializes patented regenerative medicine utilizing noninvasive ultrasound or shockwaves for tissue, musculoskeletal, and vascular repair. The company operates in a single reportable segment focused on medical devices, primarily the UltraMIST® system and related consumables.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Q2 2026 revenue decreased 3% year-over-year (YoY) to $9.74 million, driven by a 29% decline in UltraMIST® system unit volume and a 9% decrease in average selling price. This was partially offset by a 27% increase in consumables unit volume. Six-month revenue was flat at $19.36 million.
• Profitability: The company reported a net loss of $0.68 million in Q2 2026, compared to net income of $0.55 million in Q2 2025. The shift to a loss was driven by an operating loss of $0.28 million (vs. $1.44 million operating income in prior year) due to higher operating expenses.
• Operating Expenses: Total operating expenses increased 20% YoY in Q2 to $7.70 million. Notable increases included Research & Development (up 224% to $0.63 million) and Selling & Marketing (up 15% to $1.92 million). General & Administrative expenses rose 12% to $4.90 million, primarily due to higher personnel and legal fees, partially offset by a reduction in sales tax accruals.
• Other Income/Expense: Net other expense improved significantly to $0.40 million in Q2 2026 from $0.89 million in Q2 2025. This improvement was driven by a 73% reduction in interest expense following a September 2025 debt refinancing and the non-recurrence of a $1.0 million gain from derivative liabilities in the prior year.
• Cash Flow: Operating cash flow turned positive, providing $0.82 million for the six months ended June 30, 2026, compared to a use of $0.52 million in the prior year period. This was driven by non-cash adjustments (stock-based compensation, depreciation) offsetting the net loss.

Guidance, Outlook, Risks, and Unusual Items

• Debt Refinancing: In September 2025, the company entered a new credit agreement with JPMorgan Chase, securing a $23.0 million term loan and a $5.0 million revolver. This replaced prior senior secured debt, reducing interest costs and extending maturities.
• Restatement of Prior Periods: The company restated Q2 2025 financials due to errors in sales tax accruals and revenue recognition related to extended warranties. The restatement reduced prior period revenue and increased expenses, impacting year-over-year comparisons.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026. Material weaknesses persist regarding insufficient accounting resources, revenue recognition, sales tax, and IT controls. A remediation plan is underway.
• Liquidity: Management believes current cash, operating cash flows, and revolver availability are sufficient to meet obligations for at least the next 12 months.
• Patent Sale: In August 2025, the company recognized a $5.0 million gain from the sale of a patent portfolio, which contributed to the prior year's financial results but is not recurring.
• Supply Chain Risk: The company relies on single suppliers for most component materials and finished product assembly, creating potential disruption risks.

Investor Verification Checklist

• Restatement Impact: Verify the full extent of the sales tax liability and revenue recognition adjustments made to 2025 figures to ensure accurate trend analysis.
• Internal Control Remediation: Monitor the progress of the remediation plan for material weaknesses in internal controls, as failure to remediate could lead to future restatements or delisting risks.
• Debt Covenants: Confirm ongoing compliance with financial covenants under the JPM Credit Agreement, particularly given the shift from profitability to operating losses.
• System Sales Volume: Assess the sustainability of the 29% decline in UltraMIST® system unit sales and the impact of the used equipment market on future capital sales.
• Working Capital Trends: Review the increase in inventory ($7.07 million) and accounts receivable ($5.80 million) to ensure these assets are collectible and not obsolete.